The agreement includes exclusive distribution rights for CareFusion’s AcuCare high flow nasal cannula in the U.S., San Diego, Calif.-based CareFusion said.
“This agreement with ResMed is aligned with our commitment to providing high quality respiratory products to our customers. This collaboration will help ensure our customers have access to a full portfolio of leading respiratory solutions,” respiratory solutions prez Dan Woolson said in a press release.
The device is designed to hold its shape and stay in place after fitting to allow for high flow oxygen therapy, CareFusion said.
“The combination of ResMed products with Airlife reach will help provide more patients with innovative respiratory technology. This collaboration helps position ResMed for growth beyond what we could achieve alone,” ResMed Americas prez Jim Hollingshead said in prepared remarks.
No additonal agreements or terms of the deal were disclosed.
Franklin Lakes, N.J.-based Becton agreed last October to pay a total of $58.00 a share – $49.00 in cash and 0.0777 of a BDX share – for each CFN share, representing a premium of 26% to the closing price on Oct. 3.
The deal unites 2 complementary product lines: BD makes products to deliver and administer drugs, such as disposable needles, syringes and intravenous catheters, while CareFusion makes products to store and deliver drugs, such as infusion pumps.